Our study reveals that TGFβ2 upregulates NDRG1 via the TGFβR/Smad2/3 pathway, driving GC progression and highlighting the potential role of the TGFβ2NDRG1 axis in GC‐targeted therapies. The gene discussed is NDRG1; the disease is gastric cancer.